- Home
- A-Z Publications
- Clinical Cancer Drugs
- Fast Track Listing
Clinical Cancer Drugs - Online First
Description text for Online First listing goes here...
8
results
-
-
Advancements in Cancer Therapeutics: Emerging Agents and Combination Strategies in Drug Discovery
Authors: Afzal Hussain and Ashfaq HussainAvailable online: 14 January 2025More LessIn the last few years, there have been significant advances in cancer agent research, most of which entered clinical trials after succeeding in initial preclinical studies. Here, we discuss successful accomplishments in the promising approaches of targeted therapies, immunotherapies, and combination therapies. The development in these areas includes sotorasib - targeting the mutation of KRAS for lung and pancreatic can Read More
-
-
-
Biomaterials used to Deliver Drugs for Colon Cancer Management
Authors: Namita Badoniya and Manu SharmaAvailable online: 24 December 2024More LessDespite the major advancements in cancer treatment, colon cancer (CC) is still one of the most lethal malignancies worldwide. Among various type of cancer, it is the third largest prevailing kind of cancer affecting both men and women equally. Metastatic development is particularly common in individuals with advanced stages and frequently associated with subpar response of chemotherapy and severe morbidity. The unfavorab Read More
-
-
-
Efficacy Assessment of Sulfated Flavanol Functionalized Silver Nanoparticles against MCF-7 Breast Cancer
Authors: Shweta Rajawat, B. Ramachandran and M.M. MalikAvailable online: 02 December 2024More LessAim The present research work aims to formulate a cost-effective and less toxic drug for specific and selective delivery at the tumor site. Background Existing therapeutics, such as chemo, surgery, etc., for fast-paced MCF-7 breast cancer, still face challenges, especially due to their toxic side effects. The unique properties of metal nanoparticles embedded in anti-oxidant plant polymers have sparked great interest in Read More
-
-
-
PROTAC and PROTAB: Revolutionizing Cancer Therapy by Targeted Protein Degradation
Authors: Swati Verma, Sarvesh Paliwal and Debashish ParamanickAvailable online: 15 November 2024More LessChemotherapeutic strategies that target irregularly produced or mutant proteins using monoclonal antibodies (mAbs) and tiny molecular inhibitors have been extensively employed to target cancer. However, because most intracellular proteins lack antigens or active sites with which mAbs or SMIs can engage, they have not been considered druggable targets. After extensive research, PROTACs (Proteolysis Targeting chimaera Read More
-
-
-
Revolutionizing Glioblastoma Immunotherapy Conquering Transport and Biological Challenges, Innovating Combinatorial Approaches for Unprecedented Treatment Success
Authors: Shatrudhan Prajapati and Shikha YadavAvailable online: 11 November 2024More LessGlioblastomas are the most common primary brain cancer and present many challenges in treatment, with the current standard-of-care treatments yielding a median survival rate of less than 15 months. While immunotherapy against cancer has been very effective in some cancers, its application in glioblastoma has been limited so far. The following review touches upon some of the critical challenges associated with Read More
-
-
-
Investigation of Novel Quinoline Derivatives Targeting Epidermal Growth Factor Receptors as Anticancer Agents a Computational Approach
Available online: 07 November 2024More LessBackground Newer chemical entities are created and synthesis has been made feasible by a variety of computer-aided drug design (CAAD) techniques. In addition to facilitating the visualisation of the ligand-target binding process, the application of in silico methodologies and structure-based drug design (SBDD) allows for the prediction of receptor affinities and significant binding pocket locations. Objective The goal of th Read More
-
-
-
Synergistic Action of Thymol-citral is Associated with Cell Cycle Arrest and Intracellular ROS Generation in A549 Cells
Available online: 24 October 2024More LessObjective NSCLC is the predominant form of lung cancer, often exhibiting resistance to chemotherapy. Thymol and citral have shown promise as anticancer agents in different cancer cell lines but have not been evaluated in combination against NSCLC. Hence, we planned to investigate the anticancer effect of thymol-citral combination and explore its mechanisms of action against A549 cells. Methods A549 cells were expose Read More
-
-
-
PNU-74654 Enhanced the Antiproliferative Activity of Gemcitabine by Targeting Wnt/β-Catenin Pathway in Pancreatic Cancer
Available online: 21 October 2024More LessBackground The Wnt/beta-catenin pathway is one of the pathways that is deregulated in pancreatic cancer and is reported to be associated with a poor prognosis. This indicates the need for the identification of novel agents to improve the efficacy of current therapy or have an improved efficacy. Therefore, in the present study, we explored the anticancer activity of PNU-74654 alone or in combination with gemcitabine in Read More
-